You are here

Study: E-Cigarettes May Boost Resistance of Drug-Resistant ‘Superbugs’

Lab data point to increased virulence

Despite being touted by their manufacturers as a healthy alternative to cigarettes, e-cigarettes appear in a laboratory study to increase the virulence of drug-resistant and potentially life-threatening bacteria, while decreasing the ability of human cells to kill these bacteria.

Researchers at the VA San Diego Healthcare System (VASDHS) and the University of California, San Diego (UCSD) tested the effects of e-cigarette vapor on live methicillin-resistant Staphylococcus aureus (MRSA) and human epithelial cells. MRSA commonly colonizes the epithelium of the nasopharynx, where the bacteria and the epithelial cells are exposed constantly to inhaled substances, such as e-cigarette vapor and cigarette smoke.

“The virulence of MRSA is increased by e-cigarette vapor,” said lead investigator Laura E. Crotty Alexander, MD. Exposure to e-cigarette vapor increased the virulence of the bacteria, helping MRSA to escape being killed by antimicrobial peptides and macrophages. However, she added, the vapor did not make the bacteria as aggressive as cigarette-smoke exposure did in parallel studies her group conducted.

To conduct the e-cigarette vapor experiment, the researchers grew MRSA (USA 300 strain) in culture with vapor concentrations similar to those of inhalers currently on the market. The investigators tested first for biochemical changes in the culture that are known to promote pathogen virulence and then introduced epithelial cell-killing and alveolar macrophage-killing assays.

The study was presented at the 2014 American Thoracic Society (ATS) International Conference, being held May 16–21 in San Diego, California.

The researchers looked at five factors that contribute to MRSA virulence: growth rate, susceptibility to reactive oxygen species (ROS), surface charge, hydrophobicity, and biofilm formation. In particular, e-cigarette vapor led to alterations in surface charge and biofilm formation, which conferred greater resistance to killing by human cells and antibiotics.

Crotty Alexander said that one possible contribution to the increased virulence of MRSA was the rapid change in pH induced by e-cigarette vapor. Exposure changed the pH from 7.4 to up to 8.4, making the environment highly alkalotic for both bacterial and mammalian cells. This alkalosis stresses the cells, sending them a danger signal, which leads to the activation of defense mechanisms. The bacteria make their surfaces more positively charged to avoid binding by the lethal antimicrobial peptides produced by human innate immune cells. The bacteria also form thicker biofilms, which increases their stickiness and makes MRSA less vulnerable to attack.

These changes make MRSA more virulent, the investigators say. However, when MRSA is exposed to regular cigarette smoke, their virulence is even greater. Cigarette smoke induces surface-charge changes that are 10-fold greater than that of e-cigarette exposure, alters hydrophobicity, and decreases sensitivity to reactive oxygen species and antimicrobial peptides. In a mouse model of pneumonia, MRSA exposed to cigarette smoke had four times greater survival in the lungs and killed 30% more mice compared with control MRSA. MRSA exposed to e-cigarette vapor were also more virulent in mice, with a three-fold higher survival.

Unfortunately, while e-cigarette vapor increases bacterial virulence, Crotty Alexander found that the vapor also decreases the ability of human epithelial cells to kill pathogens.

“As health care professionals, we are always being asked by patients, ‘Would this be better for me?’,” Crotty Alexander said. “In the case of smoking e-cigarettes, I hated not having an answer. While the answer isn’t black and white, our study suggests a response: even if e-cigarettes may not be as bad as tobacco, they still have measurable detrimental effects on health.”

Sources: Medical Xpress; May 18, 2014; and ATS; May 18, 2014.

Recent Headlines

Findings from ISCHEMIA trial may mean fewer stents and bypass operations for those with stable disease
Donors hope to vaccinate 450 million children each year
New Novartis drug cuts rate of crises by 45% relative to placebo
FDA says new Pentax design is easier to clean
Myovant’s drug would offer a new oral, once-daily treatment option
More research is needed to confirm the finding
Study shows "complex genetic risk architecture"
Study says yes, interventions cuts need for meds
Review of 18 studies finds that medium doses have the strongest effects